title: Predictors of all-cause 1-year mortality in implantable cardioverter defibrillator patients with chronic Chagas' cardiomyopathy.
abstract: BACKGROUND
  Implantable cardioverter defibrillators (ICDs) have been used in the treatment of either sustained ventricular tachycardia or ventricular fibrillation in patients with Chagas' cardiomyopathy. This study aimed at determining mortality rate and risk factors of all-cause 1-year mortality in primary and secondary ICD patients with Chagas' cardiomyopathy.
  
  
  METHODS
  One hundred and forty-eight Chagas' patients with ICDs were included from the Medtronic ICD Registry Latin America. All patients were followed for 1 year.
  
  
  RESULTS
  At implant, mean age was 60.1 ± 9.4 years and 72.9% were male. Mean left ventricular ejection fraction (LVEF) was 40.1 ± 11%. Mean follow-up was 12 ± 7 months. During the follow-up, 15 patients died (10.2%). Patients who died were older (64 ±10.8 years vs 59 ± 9.1; P = 0.04), had more atrial fibrillation (13.3% vs 3.8%; P = 0.02), had lower LVEF (33.4%± 9.8 vs 40.9%± 11.3; P = 0.01), and worse functional class (III/IV 40% vs 21.8%; P = 0.03). The multivariate analysis showed that two independent predictors of all-cause 1-year mortality remained statistically significant: age more than 65 (hazard ratio [HR] = 2.85, 95% confidence interval [CI] 1.77-3.92; P = 0.03) and LVEF less than 30% (HR = 2.68, 95% CI 1.57-3.79; P = 0.04).
  
  
  CONCLUSIONS
  This analysis showed that patients older than 65 years of age and with LVEF less than 30% were independent predictors of all-cause 1-year mortality in patients with chronic Chagas' cardiomyopathy.
authors.affiliation: Hospital Argerich, Buenos Aires, Argentina. ditorodario@yahoo.com.ar
authors.forename: Darío
authors.initials: D
authors.lastname: di Toro
authors.forename: Claudio
authors.initials: C
authors.lastname: Muratore
authors.forename: Luis
authors.initials: L
authors.lastname: Aguinaga
authors.forename: Luiz
authors.initials: L
authors.lastname: Batista
authors.forename: Antonio
authors.initials: A
authors.lastname: Malan
authors.forename: Oswaldo
authors.initials: O
authors.lastname: Greco
authors.forename: Chamia
authors.initials: C
authors.lastname: Benchetrit
authors.forename: Mauricio
authors.initials: M
authors.lastname: Duque
authors.forename: Adrian
authors.initials: A
authors.lastname: Baranchuk
authors.forename: Jennifer
authors.initials: J
authors.lastname: Maloney
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D002598:Chagas Cardiomyopathy / Q000401:mortality* / Q000503:physiopathology / Q000628:therapy*; D002908:Chronic Disease; D015331:Cohort Studies; D016757:Death, Sudden, Cardiac / Q000453:epidemiology; D017147:Defibrillators, Implantable / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000401:mortality / Q000503:physiopathology